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INTRODUCTION
Since its introduction, the expanded polyte-
traflouroethylene grafts (ePTFE) has become the
prosthetic graft of choice when placing artificial
arteriovenous access for hemodialysis.1-3 Standard
thickness ePTFE grafts were used initially; however,
when thin wall ePTFE grafts became available,
many centers began using this new wall configura-
tion because of its increased flexibility and ease of
handling. Thin wall grafts were used in preference
to standard thickness ePTFE grafts, despite a lack of
scientific data showing that the 2 wall configura-
tions are comparable in durability and patency rates.
There is subjective opinion that the thin wall struc-
ture might predispose patients to pseudoaneurysms
or other complications related to repeated needle
punctures of the conduit. The patency and compli-
cation rates of standard thickness stretch 6 mm
ePTFE grafts were compared with those of thin wall
stretch 6 mm ePTFE grafts (WL Gore & Associates,
Flagstaff, AZ).
MATERIALS AND METHODS
One hundred eight patients sequentially receiving
new grafts were prospectively randomized into 2
groups: those receiving standard thickness stretch 6
mm ePTFE grafts (STD) and those receiving thin wall
stretch 6 mm ePTFE grafts (THN). From September
1993 to August 1996, 56 patients received STD
grafts, and 52 patients received THN grafts. 
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Patients were then studied in the hemodialysis
center, where day of first access, the length of pri-
mary patency, the interventions (type and number)
required to maintain patency of the graft, and long-
term results were documented. Patients were also
studied for infections, occurrence of pseudoa-
neurysms, and mortality. 
All grafts were standardized to a loop forearm
placement4 between 30 and 35 cm long, except for
2 unusual cases (1 upper arm in the STD group and
1 thigh placement in the THN group). Thus these 2
patients were excluded from analysis. If the patient
had prior failed grafts or proximal arm fistulas, the
contralateral forearm was used. Except for a distal
failed radiocephalic fistula, the loop graft was the
first access in the used forearm. All patients had tem-
porary dual lumen hemodialysis catheters placed in
either the contralateral internal jugular or, rarely, in
the subclavian vein by Seldinger technique in a
attempt to allow maturation of the graft for at least
14 days. All patients received 1 g of Vancomycin as
a preoperative antibiotic, and all grafts were placed
under the sterile conditions of an operating suite.
Skin was closed by subcuticular running suture in all
patients. Anesthesia choice was made by the patient
and anesthesiologist; most often local anesthesia
with intravenous sedation was given. Randomization
of the graft type to be placed was determined in the
operating suite by having the operating room nurse
flip a coin out of the presence of the surgeons. The
selected graft was then given to the surgical team for
implantation.
The type and number of interventions for con-
tinued patency of the arteriovenous grafts were doc-
umented throughout the study. The grafts were
revised by either thrombectomy or thrombectomy
and revision. Revision was used when venous outlet
obstruction or severe stenosis was documented by
means of intraoperative arteriography. The operative
approach for revision was to expose the distal mid-
loop graft, open the graft, and perform a thrombec-
tomy with an appropriately sized Fogerty catheter.
Next, an intraoperative arteriogram was taken to see
whether there was venous outlet obstruction, and, if
present, a revision was done from the graft to vein
proximal to the anastomosis. If there was no outlet
obstruction and no other technical problem was pre-
sent causing failure, graft and skin were closed.
Interventional radiology was not used for mainte-
nance of graft patency during this study period
because most interventions now used were not avail-
able at that time.
Results were analyzed by the Student’s unpaired
t-test, life table analysis by log-rank patency curve
comparisons, Fisher’s exact test, and c 2 analysis.
Other than the 2 patients dropped from analysis
because of nonstandard graft locations, no patients
were excluded from the study follow-up, and all
cases were studied to the best of the ability of
researchers and hemodialysis center staff. 
RESULTS
Patient historical data is summarized in Table I.
The average age for study patients was 55 years
(range, 13–92 years). There were 40 men and 68
women. African Americans made up 93% of the
patient population. Nonpatency adverse outcome
data, including rates of infection (2% of the STD
group vs. 3% of the THN group), pseudoaneurysm
(6% of the STD group vs. 5% of the THN group),
and mortality (22% of the STD group vs. 19% of the
THN group), was not statistically different between
groups. Day 11 was the average day of first access of
each graft for each group. During the study, no
patient died of complications from the arteriovenous
grafts. 
During the study period, 66% of the STD group
and 73% of the THN group experienced primary
failure. Average length of primary patency ± SE of
the mean was 18.2 ± 2.1 months for the STD grafts,
compared with 12.1 ± 1.9 months for the THN
grafts (P = .03). Not all grafts could be revised;
those that couldn’t be revised had to be excluded
from continued use because of infection or pseudoa-
neurysm. Secondary patency was similarly longer for
STD grafts (22.2 ± 1.4 months) than for THN
grafts (15.2 ± 1.0 months), with P = .04. These
results are summarized in Table II. 
Life table comparisons of primary (Fig. 1) and
secondary (Fig. 2) patency with log-rank testing
showed differences in the patency curves of the 2
groups. Of the grafts placed, the percentage of STD
grafts primarily patent at 6, 12, 18 and 30 months
were 62%, 49%, 40%, and 27%, respectively (Table
IIIb). The percentage of THN grafts primarily
patent was 39% at 6 months, 35% at 12 months, 31%
Table I. Patient historical data
STD THN
Average age (years) 54 55
Hypertension 77% (43/56) 73% (38/52)
Diabetes Mellitus 48% (27/56) 50% (26/52)
Tobacco use 11% (5/56) 19% (10/52)
STD, Standard graft; THN, thin wall graft.
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at 18 months, and 4% at 30 months (Table IIIa).
The life table analysis is shown on Fig. 1. From 6 to
15 months, the STD grafts exhibited a 20% greater
patency rate than the THN grafts. From 27 months
on, more STD grafts were primarily patent. Few
patients had grafts that were functional at more than
30 months in our study period. However, as shown
in Fig. 2, secondary patency was better maintained
in both groups for 2 years, with only patients with
STD grafts having patencies that lasted to 36
months (Tables IVa, IVb).
As noted in Table II, many grafts were salvaged
with interventions. Of the 37 STD revisions, 14
consisted of simple thrombectomy with no identifi-
able cause, whereas 23 required venous limb bypass.
Of the 31 THN revisions, 15 were simple thrombec-
tomies, and 16 required venous limb bypass. These
rates of thrombectomies performed were not signif-
icantly different between the groups. Additional
interventions were performed for cumulative paten-
cy: 1 additional simple thrombectomy was done in a
STD graft (after prior revision), and 2 simple
thrombectomies were done in THN grafts (again,
after prior revisions.)
Many of the study patients had previous arteri-
ovenous grafts (35% of the STD group and 52% of
the THN group). c 2 analysis showed no difference
between the STD group and the THN group with
respect to the number of patients without previous
grafts. Of those patients with previous grafts, most
had 2 or more previous arteriovenous grafts (58% of
the STD group and 64% of the THN group). 
The STD grafts had a mean follow-up examina-
tion time of 38.1 ± 0.8 months, as compared with a
mean follow-up examination time of 35.1 ± 1.0
months for the THN grafts. This difference has a
Fig. 1. Primary patency curves for patients with standard and thin wall arteriovenous grafts.
Table II. Patency times
N 10 patency (months) N revised Initial 20 patency (months) N revised Final 20 patency (months)
STD 56 18.2 ± 2.1 37 20.9 ± 1.9 9 22.2 ± 1.4
THN 52 12.1 ± 1.9 31 13.7 ± 1.8 7 15.2 ± 1.0
P .03 .007 .04
N, Number; 10, primary; 20, secondary. 
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Fig. 2. Secondary patency curves for patients with standard and thin wall arteriovenous grafts. 
Table IIIb. Primary patency life table data—standard wall grafts
Cumulative patency 
Time (mo) Grafts at risk Failure Withdrawn rate (percent) SE (percent)
0 55 9 4 100 0.0
3 42 4 2 74.5 5.9
6 36 2 1 63.6 6.4
9 33 2 3 58.2 6.7
12 28 1 1 49.1 6.7
15 26 2 1 45.5 6.7
18 23 1 1 40.0 6.6
21 22 0 0 38.2 6.5
24 22 3 3 38.2 6.5
27 19 2 2 32.7 6.3
30 17 1 4 29.1 6.0
33 12 4 4 20.0 5.4
36 8 0 0 12.7 4.5
Table IIIa. Primary patency life table data—thin wall grafts
Cumulative patency 
Time (mo) Grafts at risk Failure Withdrawn rate (percent) SE (percent)
0 51 21 3 100 0.0
3 27 5 1 49.0 7.0
6 21 1 1 39.2 6.8
9 20 1 1 37.3 6.8
12 19 1 1 35.3 6.7
15 18 1 1 33.3 6.6
18 17 0 0 31.4 6.5
21 17 3 2 31.4 6.5
24 12 3 2 21.6 5.8
27 7 3 1 11.8 4.5
30 3 2 1 3.9 2.7
33 0 0 0 0
36 0 0 0 0
JOURNAL OF VASCULAR SURGERY
468 Lenz et al Sepember 1998
significant P value of .03 by Student’s unpaired t-
test. More standard grafts were initially enrolled at
the beginning of the study because of the nature of
the randomization process, but the final distribution
occurred during graft placement. 
DISCUSSION
Patency rates and complications of the wall mod-
ifications to artificial grafts for hemodialysis access
have been studied for many years in an attempt to
ameliorate the disadvantages of prosthetics in
hemodialysis. The modifications to prosthetic mate-
rial itself in grafts have included changing the wall
structure, adding luminal or extramural coatings,
and incorporating layers. Dacron as a graft material
had patency, bleeding, and wall integrity difficulties.
Adding a coating of intraluminal Teflon did not suf-
ficiently improve the results of a graft based on
Dacron, leading most surgeons to abandon it.5,6
The use of a silicone coating to decrease bleeding
did not contribute to durable access when applied to
ePTFE.7 One attempt to reduce the effects of nee-
dle punctures on graft function was the hemocyte
prosthesis. This PTFE graft incorporated a cannula-
tion area that protected the rest of the conduit from
punctures. However, this device was plagued with
rates of thrombosis and infection that precluded its
acceptance as a dialysis alternative.8 One graft used a
corethane/polyester composite construction, with
the corethane fibers in a spun 30 to 60 m m pore
layer in the lumen and the polyester reinforcing the
outer layer. Although this graft has had less bleeding
and equal patency in animal models, it has not yet
been applied to humans.9
When just ePTFE material itself is studied as a
variable in access graft outcomes, there is less in the
literature comparing differences in ePTFE configura-
tions. Tordior et al showed that the evolution of
ePTFE to a “stretch” configuration is superior to the
older, nonstretch configurations. They hypothesized
Table IVa. Secondary patency life table data—thin wall grafts
Cumulative patency 
Time (mo) Grafts at risk Failure Withdrawn rate (percent) SE (percent)
0 44 0 1 100 0.0
3 43 1 1 97.7 3.2
6 41 0 0 93.0 3.9
9 41 0 1 93.0 3.9
12 40 1 0 90.7 4.4
15 39 5 5 88.4 4.9
18 34 2 2 79.1 6.4
21 30 8 8 67.4 7.1
24 22 8 8 48.8 7.6
27 14 9 9 30.2 7.1
30 5 5 5 9.3 6.8
33 0 0 0 0 0.44
36 0 0 0 0
Table IVb. Secondary patency life table data—standard wall grafts
Cumulative patency 
Time (mo) Grafts at risk Failure Withdrawn rate (percent) SE (percent)
0 40 1 1 100 0.0
3 39 1 1 97.4 2.5
6 37 0 0 92.3 4.3
9 37 0 0 92.3 4.3
12 37 2 1 92.3 4.3
15 34 2 2 84.6 5.8
18 32 1 5 79.5 6.5
21 26 1 1 64.1 7.7
24 24 3 3 59.0 7.9
27 21 4 4 51.3 8.0
30 18 6 6 43.6 8.0
33 12 4 4 28.2 7.2
36 8 0 0 15.4 6.1
that this advantage was caused by less intimal hyper-
plasia from poor compliance match problems.10 Our
group’s prior study demonstrated superior short-
term durability of standard thickness (0.64 mm)
ePTFE grafts in comparison with thin wall (0.37
mm) ePTFE grafts,11 but longer follow-up study of
the grafts was needed. No other published study has
compared the performance of differing wall thick-
nesses on arteriovenous graft outcomes. One study
looked at similar thickness ePTFE grafts from differ-
ent manufacturers,12 but the material variable in that
study was the presence or absence of an outer wrap
layer of PTFE on the conduit.
Most arteriovenous graft failure ultimately
results from venous outflow tract stenosis,12 but
other causes of failure include pseudoaneurysms,
patient hypotension, hypercoagulable states, disad-
vantaged inflow and outflow vessels, and graft infec-
tion. This study attempted to control as many vari-
ables as possible in angioaccess surgery and prospec-
tively randomize patients so that differences in graft
failure could be attributed to the material wall thick-
ness itself. The forearm loop configuration was
adhered to as much as possible to avoid the influ-
ence of configuration effects on graft outcome that
other studies have noted.13 At an average follow-up
examination time of 36.7 months overall for the
grafts, mean primary duration of patency (as well as
duration of secondary patency) was greater in the
patients with the STD ePTFE grafts. The difference
in follow-up examination time averages between the
2 groups probably does not have clinical signifi-
cance, because most patency failures occurred before
30 months in our patients, less than either group’s
mean follow-up examination time. Additionally, the
difference is only 3 months, a clinically small differ-
ence given the 36 months average time in a
hemodialysis population. 
Our data does not explain the differences in the
grafts. The initial concern of propensity of the THN
graft to pseudoaneurysm formation was not seen in
our patients. One explanation for this is that the
thick wall configuration may have greater resistance
to kinking and compression from tunnel tract
hematomas and thrombus. The thicker wall may also
provide a more stable platform for needle hole
thrombus plugging. Patient differences may also
account for the outcomes; however, the current
study minimized as many variables as possible. This
study’s patency rates are less than those described by
most groups, with previously published secondary
patency rates of stretch ePTFE grafts ranging from
87% to 96% at 6 months and from 86% to 93% at 12
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months.1,4,12,14,15 Our patency rates were, at best,
70% to 80% at 6 months and 55% to 75% at 12
months. In a newly published study from New
Hampshire comparing all types of dialysis access,
secondary patency at 1 year for 215 ePTFE grafts
was 59%,10 not significantly different from the 64%
1-year secondary patency rate at our institution.
We found a significant difference between the 2
graft configurations. The differences were present in
both the intermediate period (6–12 months) of graft
use, and toward the end of the life of the access (>27
months.) Because accesses were continually salvaged
by revision as needed for the more difficult patients,
secondary patencies converged in early follow-up
between the 2 groups. The numbers of patients with
grafts after 30 months declines in our series; howev-
er, when the literature on graft results in hemodialy-
sis access is considered in overview, most patients
experience failure before 30 months. More patients
with STD wall grafts had functioning accesses for
more months with less interventions. We conclude
that, overall, standard thickness ePTFE grafts, as
opposed to thin wall configurations, should be used
when constructing new ePTFE hemodialysis pros-
thetics access. 
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Dr Mitchell H. Goldman Dr Valentine, Dr Seeger,
President Clagett, members, and guests. I’d like to thank
the society for the opportunity to comment on this inter-
esting paper. Part of the reason I’m happy to do this is
because it correlates with a prejudice of mine. We had
some really bad experience with thin wall PTFE grafts and
reverted to the standard traditional graft. However, most
of our bad experiences were related to pseudoaneurysm
formation and bleeding, and I was surprised to see that
they did not have the same experience in Florida. Perhaps
it’s our East Tennessee dialysis units. But as I mentioned,
we did revert to standard grafts.
Dr Lenz and her colleagues showed decreased prima-
ry and secondary patency of their thin-wall PTFE when
compared with standard wall grafts. The study is a ran-
domized prospective study, and therefore, in the tradition
that Dr Clagett is about to begin, should be paid attention
to. Although there may be some inherent flaws, there are
too few to really comment on. And I just have 1 question
for the authors. Of the primary failures reported in each
group, how many were revised and how many underwent
thrombectomy alone? Did that make a difference? One of
my prejudices is that the venous outflow tract is associat-
ed with increased internal hyperplasia. Is there a difference
in the internal hyperplasia in the outflow tract of the thin
wall vs. the standard wall grafts? And did you look at that?
The other area where internal hyperplasia might play a
role is in the needle puncture sights. Was there any way
that you could document, either through angiographic
means or direct visualization, that the puncture sights
were more stenotic or more sclerosed?
I’d like to thank the authors for providing me, in
advance and in a timely way, a copy of their manuscript. I
commend it to your reading. Again many thanks to the
Society for giving me the opportunity to make this com-
mentary.
Dr Barbra J. Lenz I wish to thank Dr Goldman for his
kind insights. We also were surprised by the low rate of
pseudoaneurysms in the thin wall group. We were expect-
ing a much higher rate. We’re not sure why that didn’t
turn out to be so, except that our hemanalysis nurses have
a wonderful time putting on clamps, rather than just hold-
ing pressure, to provide postdialysis bleeding stoppage. As
far as revising primary failure, most of our grafts were
revised, rather than only thrombectomized; approximate-
ly 90% were revised. This was done primarily because of
outflow tract stenosis at the venous anastomoses. This was
documented by means of intraoperative arteriogram. As
far as the puncture sights, the intraoperative arteriograms
did not reveal any stenosis at the puncture sights. It was
just all outflow stenosis, the standard internal hyperplasia
that causes most of the graft failures.
I’d like to ask whether Dr Goldman’s patients were all
receiving dialysis at the same center? We have a number of
different centers in Texas, some of which use clamps and
some of which use direct digital pressure.
These cases were all at our dialysis center at the uni-
versity medical center in Jacksonville, and we did have a
high rate of turnover of hemodialysis nurses during this
time; clamps and digital pressure were both used, but pri-
marily clamps were used.
Thank you.
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